Investigators sought to describe the patterns of post-progression outcome for patients with HR+/HER2- advanced breast cancer treated with endocrine therapy and a CDK4/6 inhibitor.

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine therapy alone. The monarchE trial showed improved OS and IDFS rates with ...

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially ...

More than 40% of Americans with estrogen receptor (ER)-low early breast cancer did not receive endocrine therapy, analysis of a national database showed. Omitting endocrine therapy in ER-low breast ...

And so we really need more research into how to optimize these patients long-term, especially when we generally do not use menopausal hormone therapy in hormone receptor positive breast cancer.

New review reveals how non-genomic estrogen signaling undermines treatment response and fuels tumor progression Hormone receptor–positive breast ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

Conclusions The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer. (ClinicalTrials.gov ...

At the San Antonio Breast Cancer Symposium, researchers reported that real-time monitoring with smart pill bottles significantly improved adherence to adjuvant endocrine therapy compared with standard ...

Among breast cancer survivors who became pregnant, 34% resumed endocrine therapy (ET) by 2 years postdelivery, with a 19% cumulative incidence of subsequent breast cancer events at 10 years. The ...

The mean change from baseline in the mean daily frequency of moderate-to-severe vasomotor symptoms at week 4 was −6.5 and −3.0 episodes for those receiving elinzanetant and placebo, respectively.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...